BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence

Masseter Muscle Prominence Clinical Trial

Official title:
BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: A Phase 2b, Multicenter, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study

Status Completed

Clinical Trial Summary

Based on the results of the Phase 2 Study 191622-130 [NCT02010775], the current Phase 2b study is designed to further evaluate the safety and efficacy of BOTOX® for the treatment of Masseter Muscle Prominence (MMP) in adults.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Masseter Muscle Prominence

Clinical Trial Details

NCT number	NCT03861936
Study type	Interventional
Source	Allergan
Contact
Status	Completed
Phase	Phase 2
Start date	May 16, 2019
Completion date	July 2, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06068855` - A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants	Phase 3
Recruiting	`NCT06137287` - A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants	Phase 3
Completed	`NCT04073303` - BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence	Phase 3
Recruiting	`NCT06399718` - A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants	Phase 3
Recruiting	`NCT06387394` - A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence	Phase 3